InvestSMART

Mesoblast Limited (ASX:MSB)

ALERT: Price-sensitive ASX Announcement for MSB
Current share price for MSB : $1.950 -0.73 (-27.24%)+
Announcement
Release
29 Jan 2026 10:05AM
Price at Release
$2.680
Full Release
download
Summary
Mesoblast Limited's quarterly cash flow report for the period ending December 31, 2025, highlights several key financial and operational activities. The company reported strong sales of its product Ryoncil®, with gross sales reaching US$35 million and net revenues US$30 million, marking a 60% increase from the previous quarter. Mesoblast entered into a new non-dilutive US$125 million credit line at a lower interest rate of 8% per annum, securing financial flexibility and reducing its debt costs. The company ended the quarter with US$130 million in cash and a net operating cash outflow of US$16 million. Mesoblast anticipates reduced cash outflows moving forward, supported by revenue projections and stringent expense management. The company continues to progress with its clinical programs, including trials for the label expansion of Ryoncil® and other pipeline products like rexlemestrocel-L for chronic discogenic low back pain. The report also details financing activities, including repayment and restructuring of previous debt obligations.
Key Points
  • Ryoncil® net revenues increased to US$30 million.
  • Entered a US$125 million credit facility at 8% interest.
  • Cash balance at December 31, 2025, was US$130 million.
  • Net operating cash outflow for the quarter was US$16 million.
  • Anticipated reduction in net cash spend over future periods.
  • Ryoncil® pivotal trial for label extension to commence.
  • Positive FDA feedback on rexlemestrocel-L for chronic pain.
  • Progress in clinical trials and commercial manufacturing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.